NTLA250117C50000
- 0.20
- 0.000.00%
Intellia Therapeutics Newsroom
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $45
Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $12
Goldman Sachs Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $12
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $40 to $45
Intellia Therapeutics Is Maintained at Outperform by Oppenheimer
Intellia Therapeutics Analyst Ratings
Oppenheimer Keeps Their Buy Rating on Intellia Therapeutics (NTLA)
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $50
Morgan Stanley Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $56
Analysts' Top Healthcare Picks: Inozyme Pharma (INZY), Intellia Therapeutics (NTLA)
Intellia Therapeutics Is Maintained at Overweight by Wells Fargo
Intellia Therapeutics Analyst Ratings
BMO Capital Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $50
Intellia Therapeutics (NTLA) Receives a Buy From Evercore ISI
Wells Fargo Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $60
Wells Fargo Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $60
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $29
Strategic Realignment and Pipeline Potential Drive Buy Rating for Intellia Therapeutics
RBC Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $47
RBC Cuts Price Target on Intellia Therapeutics to $47 From $54, Keeps Outperform, Speculative Risk